Growth and productivity of juvenile banana prawns, Penaeus merguiensis in natural and laboratory systems

Abstract only.Growth and survival of Penaeus merguiensis juveniles were measured over four years in the Norman River estuary, south-eastern Gulf of Carpentaria. Growth in carapace length for the first 8-9 weeks after settlement was essentially linear and averaged 1.2 mm/week in summer at 29.5°C and 0.45 mm/week in winter at 19.5°C. A comparison of different cohorts under varying temperatures and salinities indicated that growth was temperature- but not salinity-dependent. Survival of newly settled postlarvae varied seasonally and was highest in spring (October-November). In the laboratory, a study of moulting rate and moult increment at 15, 20, 25, 30 and 35°C demonstrated that the optimal temperature for growth was 25-30°C. Survival of juveniles was also highest at intermediate temperatures. Effects of salinity and food ration amounts are discussed

Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia.

The occurrence of non-epileptic hyperkinetic movements in the context of developmental epileptic encephalopathies is an increasingly recognized phenomenon. Identification of causative mutations provides an important insight into common pathogenic mechanisms that cause both seizures and abnormal motor control. We report bi-allelic loss-of-function CACNA1B variants in six children from three unrelated families whose affected members present with a complex and progressive neurological syndrome. All affected individuals presented with epileptic encephalopathy, severe neurodevelopmental delay (often with regression), and a hyperkinetic movement disorder. Additional neurological features included postnatal microcephaly and hypotonia. Five children died in childhood or adolescence (mean age of death: 9 years), mainly as a result of secondary respiratory complications. CACNA1B encodes the pore-forming subunit of the pre-synaptic neuronal voltage-gated calcium channel Cav2.2/N-type, crucial for SNARE-mediated neurotransmission, particularly in the early postnatal period. Bi-allelic loss-of-function variants in CACNA1B are predicted to cause disruption of Ca2+ influx, leading to impaired synaptic neurotransmission. The resultant effect on neuronal function is likely to be important in the development of involuntary movements and epilepsy. Overall, our findings provide further evidence for the key role of Cav2.2 in normal human neurodevelopment.MAK is funded by an NIHR Research Professorship and receives funding from the Wellcome Trust, Great Ormond Street Children's Hospital Charity, and Rosetrees Trust. E.M. received funding from the Rosetrees Trust (CD-A53) and Great Ormond Street Hospital Children's Charity. K.G. received funding from Temple Street Foundation. A.M. is funded by Great Ormond Street Hospital, the National Institute for Health Research (NIHR), and Biomedical Research Centre. F.L.R. and D.G. are funded by Cambridge Biomedical Research Centre. K.C. and A.S.J. are funded by NIHR Bioresource for Rare Diseases. The DDD Study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003), a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute (grant number WT098051). We acknowledge support from the UK Department of Health via the NIHR comprehensive Biomedical Research Centre award to Guy's and St. Thomas' National Health Service (NHS) Foundation Trust in partnership with King's College London. This research was also supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre. J.H.C. is in receipt of an NIHR Senior Investigator Award. The research team acknowledges the support of the NIHR through the Comprehensive Clinical Research Network. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Department of Health, or Wellcome Trust. E.R.M. acknowledges support from NIHR Cambridge Biomedical Research Centre, an NIHR Senior Investigator Award, and the University of Cambridge has received salary support in respect of E.R.M. from the NHS in the East of England through the Clinical Academic Reserve. I.E.S. is supported by the National Health and Medical Research Council of Australia (Program Grant and Practitioner Fellowship)

Colour and size variation within a population of Brachaspis collinus (Hutton) (Orthoptera: Acrididae)

There are at least two types of biological variation, i.e., “group, or geographical variation” referring to differences between populations and "individual variation” referring to differences among individuals in a single population. Variation among individuals has been of interest in descriptive zoology and especially to the taxonomist as a reaction to the ‘type’ species concept. Moreover, the occurrence of individual variation and its significance to the species is an important part of ecological and evolutionary study. A population can adapt itself to a varying environment either by producing phenotypes with a wide tolerance and plasticity, or by producing a wide variation of individuals, with certain individuals sacrificed to the advantage of the population. Geographical and individual variation in size of animals is common, especially among insects. Widespread species which show similar adaptation to similar conditions are often considered in terms of "ecological rules”. One of these is Bergmann's Rule concerning the size of individuals and temperature. Briefly, Bergmann's Rule predicts larger sized individuals in cooler parts of a species range. The validity of the rule has been shown for many birds and mammals but reports on its application to poikilotherms conflict. Bigelow (in press), recorded a significant clinal increase in size with increase in altitude within certain populations of two species of New Zealand Alpine Grasshoppers (Acrididae), viz: Brachaspis nivalis (Hutton) and Sigaus australis (Hutton) but size variation has not been investigated in populations of other New Zealand species of grasshoppers. Brachaspis collinus (Hutton), a fairly large brachypterous species, occurs above 3,000' in the mountains from N.W. Nelson to Arthur's Pass in the South Island. It was therefore of interest to determine the relationship of size and altitude in B. collinus to further test the applicability of Bergmann's Rule to New Zealand Grasshoppers. The widespread occurrence of geographical variation among populations in colour and pattern has been noted by Mayr (1963) and by many others. This variation has been recorded for adult specimens of New Zealand grasshoppers by Bigelow (in press), who also notes a colour polymorphism in the adults of B. collinus in the more southern parts of its distribution. However, the extent of the variation of adults and the variation of juveniles in this species requires further study. This study has been concentrated on one population of B. collinus in an attempt to determine the extent and possible significance of the individual variation

Production biology of the upland bully Philypnodon breviceps Stokell in a small Canterbury lake

The purpose of this thesis was to investigate the relationships between food intake, biomass and production of a population of the upland bully, Philypnodon breviceps Stokell, in a small Canterbury lake. Early studies of fish populations were confined essentially to descriptive aspects of a species' biology (food habits, growth, life history and reproductive biology). However the inadequacy of this type of information for a complete understanding of the ecology of a fish population, particularly with respect to management of fisheries, was soon realised (Ricker, 1946), and in recent years increasing emphasis has been placed on the more functional aspects of aquatic ecosystems. This approach has been stimulated by the early contributions of such workers as Thienemann (1926) and Elton (1927), who first introduced the concepts of trophic levels, ecological niches and ecological pyramids. With the application of the laws of thermodynamics to ecological theory at about the same time (for example, Lotka, 1925), it became possible to consider the dynamic processes associated with the flow of energy through successive levels of a food chain. This trophic-dynamic approach was clearly outlined in the classic paper of Lindemann (1942), which provided a basic model for subsequent research in ecological energetics

Social and Cultural Factors Influence African American Men's Medical Help Seeking

Objective: To examine the factors that influenced African American men’s medical help seeking. Method: Thematic analysis of 14 focus groups with 105 older, urban African American men. Results: African American men described normative expectations that they did not go to the doctor and that they were afraid to go, with little explanation. When they did go, men reported that they were particularly uncomfortable with the tone physicians used when talking to them. Providers often made recommendations but offered the men little useful information on how to make lifestyle and behavior changes. Following receipt of care, spouses, medical test results, and men’s desire to fulfill social roles were key motivating and instrumental factors in following medical advice. Conclusions: African American men’s medical help seeking seemed to be negatively influenced by social norms and patient-provider interactions but positively influenced by spouses and the desire to fulfill social roles

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Background The current tuberculosis (TB) drug development pipeline is being re-populated with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to shorten TB therapy by exerting a bactericidal effect on non-replicating bacilli. Based on results from preclinical and early clinical studies, a four-drug combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ) regimen was identified with treatment-shortening potential for both drug-susceptible (DS) and drug-resistant (DR) TB. This trial aimed to determine the safety and efficacy of BPaMZ. We compared 4 months of BPaMZ to the standard 6 months of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) in DS-TB. 6 months of BPaMZ was assessed in DR-TB. Methods SimpliciTB was a partially randomised, phase 2c, open-label, clinical trial, recruiting participants at 26 sites in eight countries. Participants aged 18 years or older with pulmonary TB who were sputum smear positive for acid-fast bacilli were eligible for enrolment. Participants with DS-TB had Mycobacterium tuberculosis with sensitivity to rifampicin and isoniazid. Participants with DR-TB had M tuberculosis with resistance to rifampicin, isoniazid, or both. Participants with DS-TB were randomly allocated in a 1:1 ratio, stratified by HIV status and cavitation on chest radiograph, using balanced block randomisation with a fixed block size of four. The primary efficacy endpoint was time to sputum culture-negative status by 8 weeks; the key secondary endpoint was unfavourable outcome at week 52. A non-inferiority margin of 12% was chosen for the key secondary outcome. Safety and tolerability outcomes are presented as descriptive analyses. The efficacy analysis population contained patients who received at least one dose of medication and who had efficacy data available and had no major protocol violations. The safety population contained patients who received at least one dose of medication. This study is registered with ClinicalTrials.gov (NCT03338621) and is completed. Findings Between July 30, 2018, and March 2, 2020, 455 participants were enrolled and received at least one dose of study treatment. 324 (71%) participants were male and 131 (29%) participants were female. 303 participants with DS-TB were randomly assigned to 4 months of BPaMZ (n=150) or HRZE (n=153). In a modified intention-to-treat (mITT) analysis, by week 8, 122 (84%) of 145 and 70 (47%) of 148 participants were culture-negative on 4 months of BPaMZ and HRZE, respectively, with a hazard ratio for earlier negative status of 2·93 (95% CI 2·17–3·96; p<0·0001). Median time to negative culture (TTN) was 6 weeks (IQR 4–8) on 4 months of BPaMZ and 11 weeks (6–12) on HRZE. 86% of participants with DR-TB receiving 6 months of BPaMZ (n=152) reached culture-negative status by week 8, with a median TTN of 5 weeks (IQR 3–7). At week 52, 120 (83%) of 144, 134 (93%) of 144, and 111 (83%) of 133 on 4 months of BPaMZ, HRZE, and 6 months of BPaMZ had favourable outcomes, respectively. Despite bacteriological efficacy, 4 months of BPaMZ did not meet the non-inferiority margin for the key secondary endpoint in the pre-defined mITT population due to higher withdrawal rates for adverse hepatic events. Non-inferiority was demonstrated in the per-protocol population confirming the effect of withdrawals with 4 months of BPaMZ. At least one liver-related treatment-emergent adverse effect (TEAE) occurred among 45 (30%) participants on 4 months of BPaMZ, 38 (25%) on HRZE, and 33 (22%) on 6 months of BPaMZ. Serious liver-related TEAEs were reported by 20 participants overall; 11 (7%) among those on 4 months of BPaMZ, one (1%) on HRZE, and eight (5%) on 6 months of BPaMZ. The most common reasons for discontinuation of trial treatment were hepatotoxicity (ten participants [2%]), increased hepatic enzymes (nine participants [2%]), QTcF prolongation (three participants [1%]), and hypersensitivity (two participants [<1%]).Interpretation For DS-TB, BPaMZ successfully met the primary efficacy endpoint of sputum culture conversion. The regimen did not meet the key secondary efficacy endpoint due to adverse events resulting in treatment withdrawal. Our study demonstrated the potential for treatment-shortening efficacy of the BPaMZ regimen for DS-TB and DR-TB, providing clinical validation of a murine model widely used to identify such regimens. It also highlights that novel, treatment-shortening TB treatment regimens require an acceptable toxicity and tolerability profile with minimal monitoring in low-resource and high-burden settings. The increased risk of unpredictable severe hepatic adverse events with 4 months of BPaMZ would be a considerable obstacle to implementation of this regimen in settings with high burdens of TB with limited infrastructure for close surveillance of liver biochemistry. Future research should focus on improving the preclinical and early clinical detection and mitigation of safety issues together and further efforts to optimise shorter treatments